Back to results
US 2017/0152206 A1Published application
IRE-1alpha INHIBITORS
AssigneeMannKind Corporation
InventorsJohn B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
Life of this patent
Estimating the term…
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Claims20
An IRE-1α inhibitor having a structure
A method of treating a disease comprising:
- administering an IRE-1α inhibitor having a structure
- and
- treating the disease.
Dependencies are inferred from the claim text.